Sign up to save your podcasts
Or
Share Does Nintedanib Benefit Certain Subgroups of IPF Patients More than Others? An Analysis of the Data from the INPULSIS Trials
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Does Nintedanib Benefit Certain Subgroups of IPF Patients More than Others? An Analysis of the Data from the INPULSIS Trials
Dr. Nitin Seam talks with Drs. Ulrich Costabel and Athol Wells about idiopathic pulmonary fibrosis and which patients may benefit from nintedanib treatment. They discuss the INPULSIS trials and Dr. Costabel's article in the January 15 issue of AJRCCM.
View all episodes
By American Thoracic Society
4
3636 ratings
Dr. Nitin Seam talks with Drs. Ulrich Costabel and Athol Wells about idiopathic pulmonary fibrosis and which patients may benefit from nintedanib treatment. They discuss the INPULSIS trials and Dr. Costabel's article in the January 15 issue of AJRCCM.
More shows like Out of the Blue: An AJRCCM Podcast
View all
EMCrit FOAM Feed
1,867 Listeners
JAMA Editors' Summary
136 Listeners
NEJM This Week
322 Listeners
JAMA Clinical Reviews
498 Listeners
CHEST Journal Podcasts
64 Listeners
ATS Breathe Easy
36 Listeners
The Curbsiders Internal Medicine Podcast
3,354 Listeners
Core IM | Internal Medicine Podcast
1,147 Listeners
Annals On Call Podcast
191 Listeners
The Internet Book of Critical Care Podcast
696 Listeners
JAMA Medical News
93 Listeners
Run the List
248 Listeners
Critical Care Scenarios
258 Listeners
The Curious Clinicians
374 Listeners
Critical Care Time
268 Listeners